To test the hypothesis whether CD8 T-cells played a part in the enhanced efficacy of the combination treatment, we selectively depleted CD8 T cells in the MCA205 model, using IP injection of clone 53–6.7 from the 17th day post tumor implantation (schematic Figure 2a). Here, CD8A is linked to neoplasm.